Erich‐Franz Solomayer

ORCID: 0000-0002-2622-5676
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Breast Cancer Treatment Studies
  • Cancer Cells and Metastasis
  • HER2/EGFR in Cancer Research
  • Advanced Breast Cancer Therapies
  • Bone health and treatments
  • Cancer Diagnosis and Treatment
  • Breast Lesions and Carcinomas
  • Cancer Genomics and Diagnostics
  • Cancer Treatment and Pharmacology
  • Ovarian cancer diagnosis and treatment
  • Radiopharmaceutical Chemistry and Applications
  • Uterine Myomas and Treatments
  • Endometrial and Cervical Cancer Treatments
  • Cancer Immunotherapy and Biomarkers
  • Endometriosis Research and Treatment
  • Immunotherapy and Immune Responses
  • Reproductive Biology and Fertility
  • Surgical Simulation and Training
  • Minimally Invasive Surgical Techniques
  • Medical and Health Sciences Research
  • Estrogen and related hormone effects
  • Assisted Reproductive Technology and Twin Pregnancy
  • Pregnancy and preeclampsia studies
  • Pelvic floor disorders treatments
  • Cancer Risks and Factors

Saarland University
2016-2025

Klinik für Frauenheilkunde
2015-2024

Universitätsklinikum des Saarlandes
2015-2024

University Medical Center
2023

Universitäts-Frauenklinik des Saarlandes
2013-2022

Weatherford College
2021

University Medical Center Hamburg-Eppendorf
2016

Istituti Ospitalieri di Cremona
2016

European Institute of Oncology
2016

Universität Hamburg
2016

Bisphosphonates are effective against the increased bone resorption caused by certain diseases because they inhibit activity of osteoclasts. In patients who have breast cancer and metastatic disease, bisphosphonate clodronate (clodronic acid) reduces frequency skeletal complications. Experiments in animals preliminary clinical observations indicate that early therapy incidence new bony metastases cancer. We investigated effects on extent with

10.1056/nejm199808063390601 article EN New England Journal of Medicine 1998-08-06

Approximately 30% of the patients with primary breast cancer who have no axillary lymph node involvement (i.e., negative) at time surgery will relapse within 10 years; 10%-20% distant metastases be negative surgery. Axillary dissection, as a surgical procedure, is associated frequent complications. A possible alternative to nodal dissection in terms prognosis may immunocytochemical detection tumor cells bone marrow.In prospective study, value cell (TCD) marrow was compared after surgery.Data...

10.1093/jnci/88.22.1652 article EN JNCI Journal of the National Cancer Institute 1996-11-20

10.1093/annonc/mdu455 article EN publisher-specific-oa Annals of Oncology 2014-09-16

Polyhydramnios is defined as a pathological increase of amniotic fluid volume in pregnancy and associated with increased perinatal morbidity mortality. Common causes polyhydramnios include gestational diabetes, fetal anomalies disturbed swallowing fluid, infections other, rarer causes. The diagnosis obtained by ultrasound. prognosis depends on its cause severity. Typical symptoms maternal dyspnea, preterm labor, premature rupture membranes (PPROM), abnormal presentation, cord prolapse...

10.1055/s-0033-1360163 article EN other-oa Geburtshilfe und Frauenheilkunde 2013-12-20

Abstract Cervical cancer is a consequence of persistent infection with human papillomaviruses (HPV). Progression to malignancy linked an inflammatory microenvironment comprising T-helper-17 (Th17) cells, T-cell subset protumorigenic properties. Neoplastic cells express only low endogenous levels the Th17 chemoattractant CCL20, and therefore, it unclear how are recruited cervical tissue. In this study, we demonstrate that CCL20 was predominantly expressed in stroma squamous cell carcinomas...

10.1158/0008-5472.can-15-0732 article EN Cancer Research 2015-12-03

// Susanne V. Schmidt 1 , Stefanie Seibert 2 Barbara Walch-Rückheim Benjamin Vicinus Eva-Maria Kamionka Jennifer Pahne-Zeppenfeld Erich-Franz Solomayer 3 Yoo-Jin Kim 4 Rainer M. Bohle Sigrun Smola 1, Center for Molecular Medicine Cologne and Institute of Virology, University Cologne, Germany Saarland University, Homburg/Saar, Department Gynecology Obstetrics, Pathology, Correspondence to: Smola, e-mail: sigrun.smola@uks.eu Keywords: cervical cancer, human papilloma virus, dendritic...

10.18632/oncotarget.3249 article EN Oncotarget 2015-03-20

Population-based estimates of the long-term risk loco-regional recurrence and distant metastases breast cancer (BRC) patients are scant, as most published studies used hospital-based cohorts or participants clinical trials. This work aims to extend available knowledge by providing population-based cumulative BRC up 10 years after diagnosis.

10.1186/s12885-019-5710-5 article EN cc-by BMC Cancer 2019-05-30

<b><i>Introduction:</i></b> Each year the interdisciplinary AGO (Arbeitsgemeinschaft Gynäkologische Onkologie, German Gynecological Oncology Group) Breast Committee on Diagnosis and Treatment of Cancer provides updated state-of-the-art recommendations for early metastatic breast cancer. <b><i>Methods:</i></b> The evidence-based treatment cancer have been released in March 2024. <b><i>Results Conclusion:</i></b> This...

10.1159/000538596 article EN Breast Care 2024-01-01

Previous studies with animal tumors showed that bone marrow (BM) is a privileged site where potentially lethal tumor cells are controlled in dormant state by the immune system. Here, we investigated BM of breast cancer patients respect to cell content, activation status and memory T-cell content. BM-derived from primary operated (n = 90) were compared those healthy donors 10) also respective blood samples. Cytokeratin 19-positive detected nested polymerase chain reaction. Three-color flow...

10.1002/1097-0215(200102)9999:9999<::aid-ijc1152>3.0.co;2-q article EN International Journal of Cancer 2001-04-01

Abstract Background The presence of disseminated tumor cells (DTC) in bone marrow (BM) breast cancer patients is associated with reduced clinical outcome. Bisphosphonate treatment was shown to eradicate DTC from BM several studies. This controlled randomized open-label multi-center study aimed investigate the influence zoledronic acid (ZOL) on and survival (Clinical Trial Registration Number: NCT00172068). Methods Patients primary DTC-positive were ZOL plus adjuvant systemic therapy (n = 40)...

10.1186/1471-2407-13-480 article EN cc-by BMC Cancer 2013-10-15
Coming Soon ...